Priority therapy areas are respiratory, cardiology, pain and inflammation, and dermatology. The product portfolio consists of several well-established products, such as Betadine (prevention and treatment of infections in the skin and mucous membranes), Zamadol (treatment of moderate to severe pain), Astelin (treatment of allergic and non-allergic rhinitis), and newly developed leading-edge products with strong growth opportunities, such as Aldara (treatment of conditions such as actinic keratosis) and SOMA 250 mg (muscle relaxant).
 
About 90% of total sales are generated by own products. The 10 largest products contribute to 50% of total sales, and the largest of these makes up about 15% of total sales.

Meda is increasingly focusing on specialised pharmaceuticals that target smaller patient groups. Specialist pharmaceuticals often mean lower sales overhead, because marketing can be directed toward a limited, clearly defined target group. The market for specialist drugs is generally less subject to competition and less price-sensitive, compared with a traditional focus on big sellers that require massive marketing efforts in an often highly competitive market.
 
Refer to each therapy area for a shorter presentation of several products in Meda's portfolio.